Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4 - PubMed (original) (raw)

Comparative Study

Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4

S L Orloff et al. J Virol. 1993 Mar.

Abstract

Two assays for measuring inhibition of human immunodeficiency virus type 1 (HIV-1) infection by soluble CD4 (sCD4) are described. Experiments in which sCD4, HIV-1, and cell concentrations and sequence of combination, noninfectious/infectious particle ratio, and temperature were varied produced results that support the conclusion that sCD4 inhibits HIV-1 infection by two mechanisms: reversible blockage of receptor binding and irreversible inactivation of infectivity. Fresh isolates obtained from HIV-1-infected persons were tested in both assays and found to be more resistant to both mechanisms of sCD4-mediated inhibition than multiply passaged laboratory strains. Binding studies revealed similar affinities for sCD4 in detergent lysates of sensitive and resistant strains at both 4 and 37 degrees C. The avidity of intact virions for sCD4 was lower at 4 than at 37 degrees C, and in the presence of excess sCD4, less sCD4 was bound at 4 than at 37 degrees C. The avidity differences were similar for fresh isolates and laboratory strains. However, fresh isolates were more resistant to sCD4-induced shedding of envelope glycoprotein gp120 from intact virions than was the laboratory strain. Relative resistance to sCD4 by certain isolates does not represent a lower intrinsic affinity of their envelope for sCD4 or a lower capacity for sCD4 binding. Rather, an event that occurs after binding may account for the differences. This postbinding event or feature may be determined by regions of the envelope outside the CD4 binding site.

PubMed Disclaimer

Cited by

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model.
Tada T, Dcosta BM, Zhou H, Landau NR. Tada T, et al. iScience. 2023 Feb 17;26(2):106092. doi: 10.1016/j.isci.2023.106092. Epub 2023 Jan 31. iScience. 2023. PMID: 36741912 Free PMC article.
An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Tada T, Fan C, Chen JS, Kaur R, Stapleford KA, Gristick H, Dcosta BM, Wilen CB, Nimigean CM, Landau NR. Tada T, et al. Cell Rep. 2020 Dec 22;33(12):108528. doi: 10.1016/j.celrep.2020.108528. Epub 2020 Dec 1. Cell Rep. 2020. PMID: 33326798 Free PMC article.
Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells.
Su X, Wang Q, Wen Y, Jiang S, Lu L. Su X, et al. Front Microbiol. 2020 May 25;11:1063. doi: 10.3389/fmicb.2020.01063. eCollection 2020. Front Microbiol. 2020. PMID: 32523582 Free PMC article. Review.
A biophysical perspective on receptor-mediated virus entry with a focus on HIV.
Llorente García I, Marsh M. Llorente García I, et al. Biochim Biophys Acta Biomembr. 2020 Jun 1;1862(6):183158. doi: 10.1016/j.bbamem.2019.183158. Epub 2019 Dec 19. Biochim Biophys Acta Biomembr. 2020. PMID: 31863725 Free PMC article. Review.
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J, Wang Q, Xu W, Lu L, Jiang S. Pu J, et al. Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705. Viruses. 2019. PMID: 31374953 Free PMC article. Review.

References

1. Nature. 1988 Jan 7;331(6151):82-4 - PubMed
1. J Immunol. 1986 Nov 1;137(9):2937-44 - PubMed
1. Ann Intern Med. 1990 Feb 15;112(4):247-53 - PubMed
1. Ann Intern Med. 1990 Feb 15;112(4):254-61 - PubMed
1. Cell. 1990 Mar 9;60(5):747-54 - PubMed

Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4 - PubMed (original) (raw)